Beximco launches bird flu drug in Myanmar

By Elaine Rigoli

Tampa, Fla., June 9 - Beximco Pharmaceuticals Ltd. said it has launched Oseflu in Myanmar for the prevention and treatment of human cases of avian influenza (H5N1) causing bird flu.

Myanmar, which neighbors Bangladesh and has a population of more than 42 million, confirmed its first case of avian flu in March.

Beximco said it will soon be exporting about 2,000 doses of the drug to Myanmar to help combat reported outbreaks of avian flu throughout the country.

The company said it is also registering Oseflu in other countries affected by avian flu.

Beximco is a Dhaka, Bangladesh-based pharmaceuticals company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.